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Abstract
The identification of founder mutations in cancer predisposing genes is important to improve risk assessment in
geographically defined populations, since it may provide specific targets resulting in cost-effective genetic testing. Here, we
report the characterization of the BRCA1 c.190T.C (p.Cys64Arg) mutation, mapped to the RING-finger domain coding
region, that we detected in 43 hereditary breast/ovarian cancer (HBOC) families, for the large part originating from the
province of Bergamo (Northern Italy). Haplotype analysis was performed in 21 families, and led to the identification of a
shared haplotype extending over three BRCA1-associated marker loci (0.4 cM). Using the DMLE+2.2 software program and
regional population demographic data, we were able to estimate the age of the mutation to vary between 3,100 and 3,350
years old. Functional characterization of the mutation was carried out at both transcript and protein level. Reverse
transcriptase-PCR analysis on lymphoblastoid cells revealed expression of full length mRNA from the mutant allele. A green
fluorescent protein (GFP)-fragment reassembly assay showed that the p.Cys64Arg substitution prevents the binding of the
BRCA1 protein to the interacting protein BARD1, in a similar way as proven deleterious mutations in the RING-domain.
Overall, 55 of 83 (66%) female mutation carriers had a diagnosis of breast and/or ovarian cancer. Our observations indicate
that the BRCA1 c.190T.C is a pathogenic founder mutation present in the Italian population. Further analyses will evaluate
whether screening for this mutation can be suggested as an effective strategy for the rapid identification of at-risk
individuals in the Bergamo area.
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Introduction
Inactivating germline mutations of BRCA1 and BRCA2 genes
account for approximately 15% to 20% of hereditary breast and/
or ovarian cancer (HBOC) cases [1,2]. The majority of alterations
identified throughout the whole sequence of both genes are private
or detected in few families only [3], but a number of specific
mutations that appear repeatedly in ethnically defined groups or in
populations enriched with genetic isolates, because of a shared
common ancestry (founder mutations), have been reported [4].
The identification of founder mutations in various ethnic groups
and their geographical distribution has important implications for
designing mutational screening. For example, three founder
mutations in the Ashkenazi Jewish (BRCA1 c.68_69delAG, BRCA1
c.5266dupC, BRCA2 c.5946delT) and one in the Icelanders
(BRCA2 c.771_775del5), account for virtually all HBOC families
linked to BRCA genes in these populations [5–8], where,
therefore, it is worthwhile to test high-risk patients specifically
for these mutations, before considering the more expensive
complete sequence analysis of both genes. Furthermore, the
identification of recurrent genomic rearrangements of the BRCA1
and BRCA2 genes, due to founder effects, has provided a strong
rational for including the screening for these alterations in the
diagnostic setting. For instance, in the Dutch population two
distinct deletions involving exons 13 and 22 account for
approximately 25% of all BRCA1-positive families [9], while
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e86924
approximately 9% of BRCA1-positive families in the United
Kingdom carry a common exon 13 duplication [10]. As a result, in
these populations screening for specific BRCA1 rearrangements is
now part of routine genetic testing of HBOC families. Notably, the
knowledge of founder BRCA1 or BRCA2 mutations may provide
more precise estimates of the prior probability of carrying a
mutation in either genes and of the likelihood of a mutation carrier
developing cancer [11].
To date, a few BRCA founder mutations have been reported
also in the Italian population, where they appear to be limited to
geographically restricted areas (reviewed in ref. 4).
Here, we report the characterization of the BRCA1 c.190T.C
missense mutation (p.Cys64Arg), located in the gene region coding
for the RING-finger motif of the protein, which segregates with
the disease in Italian HBOC families, mostly originating from the
province of Bergamo (Northern Italy).
Materials and Methods
Ethics Statement
All subjects included in the study received genetic counseling
and provided a written informed consent for BRCA gene mutation
testing and for the use of their biological samples for research
purposes: This study was approved by the ethical committee of the
Fondazione IRCCS Istituto Nazionale dei Tumori (INT) of Milan.
Case Material
The study includes 43 apparently unrelated families carrying
the c.190T.C (p.Cys64Arg) mutation in BRCA1 exon 5, identified
among those referred for BRCA gene testing from December 1995
to December 2012 by the following institutions: Fondazione
IRCCS Istituto Nazionale dei Tumori (INT) and Istituto
Oncologico Europeo (IEO) of Milan, Azienda Ospedaliera Papa
Giovanni XXIII of Bergamo (AO-BG) and University of Florence
(Department of Biomedical, Experimental and Clinical Sciences).
The presence of the mutation was ascertained in family probands
by either denaturing high performance liquid chromatography
(DHPLC) and/or direct sequencing of all coding exons and
adjacent intronic regions of the BRCA1 and BRCA2 genes.
Sequencing of BRCA1 exon 5 was performed to identify additional
mutation carriers among the probands’ relatives.
Microsatellite analysis
A total of 76 individuals, including 43 mutation carriers and 33
non carriers, from 21 of the above families were genotyped at the
BRCA1 locus as previously described [12].
Haplotyping and estimate of mutation age
Haplotypes were constructed manually from microsatellite anal-
yses, assuming the least number of possible recombinations. Age
estimate of the BRCA1 c.190T.C mutation was carried out with the
DMLE+2.2 software program (URL: http://www.dmle.org) [13].
The DMLE input file included the full haplotypes of mutations
carriers and of non-carriers, used as controls from the general
population, for the 6 examined markers, chromosome map distances
derived from the Marshfield and/or Gene´thon sex-average genetic
maps (URL: http://www.ncbi.nlm.nih.gov/mapview/), an estimate
of population growth rate per generation and an estimate of the
proportion of sampled mutation-carrying chromosomes. The
population growth rates per generation (r) were estimated as
described [12], based on available demographic data (Italian
National Statistics Institute, ISTAT; URL: http://www.istat.it) and
assuming a time interval of 25 years per generation. The r value for
the province of Bergamo from the year 1300 to present was estimated
to be 0,0526. This index was subsequently used for mutation age
estimates. Three separate analyses were then performed, each using a
different estimate for the proportion of sampled mutation-carrying
chromosomes: 0.015, 0.01, and 0.005.
Transcript analysis
Epstein-Barr virus (EBV)-immortalized human lymphoblastoid
cell lines (LCLs) were established and cultured as described [14].
Four BRCA1 mutant and six wild-type LCLs were grown in the
absence and in the presence of cycloheximide (CHX) (100 mg/ml)
for 4 hours to account for potential degradation of unstable
transcripts via nonsense mediated mRNA decay. Total RNA was
purified and reverse transcribed into cDNA as described [14]. The
PCR reaction was performed with a forward primer in BRCA1
exon 5 (59-GCATGCTGAAACTTCTCAAC-39), and a reverse
primer in exon 6 (59-TCCAAACCTGTGTCAAGCTG-39). The
reverse primer was labeled with 6-carboxyfluorescein (6-FAM).
The fluorescent amplification products were run on a 3130
Genetic Analyzer (Applied Biosystems) using the GeneScan 500
ROX Size Standard (Applied Biosystems) as internal marker. Size
calling and quantification of peak areas were performed with
GeneMapper Software v4.0 (Applied Biosystems). The molecular
nature of the peaks was confirmed by sequencing.
Statistical Analysis
The ratios of the peak areas of the BRCA1 Dexon5q and full-
length mRNA isoforms in different samples were compared by
two-tailed Student t test using GraphPad Prism version 5.0
software and 95% confidence interval (CI).
Plasmid construction
The pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP expression
vectors, encoding anti-parallel leucine zipper motifs (Z) fused to
the N-terminal or C-terminal fragment of Green Fluorescent
Protein (NfrGFP, CfrGFP, respectively) and the plasmids encoding
N-terminal RING domains of BARD1 (amino acids 26–140) and
BRCA1 (amino acids 1–109) attached via a linker sequences to the
NfrGFP (pET11a-NfrGFP-BARD1) or CfrGFP (pMRBAD-
BRCA1-CfrGFP), were created as described [15]. The pET11a-
NfrGFP-Z and pET11a-NfrGFP-BARD1 vectors also encode a
hexahistidine (H6)-tag at the N-terminus of the NfrGFP useful for
rapid purification of the H6-tagged protein. The pMRBAD-Z-
CfrGFP and pMRBAD-BRCA1-CfrGFP (both as wild-type and
mutant forms) bear an HA epitope at the C-terminus of the
CfrGFP as a detection tag. The BRCA1 c.190T.C (p.Cys64Arg),
c.199G.T (p.Asp67Tyr) and c.181T.G (p.Cys61Gly) mutants
were obtained by direct mutagenesis of pMRBAD-BRCA1-
CfrGFP using the QuikChange XL Site-directed Mutagenesis
Kit (Stratagene) according to the manufacturer’s instruction.
Recombinant clones were checked by DNA sequencing.
GFP-fragment reassembly screening
Compatible pairs of plasmids [pET11a-NfrGFP-Z and
pMRBAD-Z-CfrGFP; pET11a-NfrGFP-BARD1 and pMRBAD-
BRCA1-CfrGFP (both as wild-type or mutant forms)] were co-
transformed into BL21-(DE3) E. coli competent cells by electro-
poration. Single colonies were screened for the occurrence of
GFP-fragment reassembly as previously described [15].Fluores-
cence was observed after excitation with long-wave (365 nm) UV
light in combination with the short pass (SP) emission filter using a
Syngene image capture system (SYNGENE) as specified by the
manufacturer.
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Purification of the reassembled GFP complexes
The H6-NfrGFP-Z/Z-CfrGFP-HA and H6-NfrGFP-BARD1/
BRCA1-CfrGFP-HA (both as wild-type or mutant forms) com-
plexes were purified from the soluble fraction of co-transformed E.
coli strain BL21-(DE3) by Immobilized Metal Affinity Chroma-
tography (IMAC) using nickel nitrilotriacetic (Ni-NTA) agarose
resin (QIAGEN), following the protocol described [15]. The
protein complexes were subjected to 13% SDS-PAGE and
visualized by Western blotting using a polyclonal anti-GFP
antibody (# 600-101-215; Rockland). Unpurified cell lysates from
induced E. coli BL21-(DE3) bacteria were similarly resolved and
visualized to detect expression levels of both NfrGFP-BARD1 and
CfrGFP-BRCA1 recombinant proteins.
Clinical and pathological characteristics
Clinical and pathological data of affected mutation carriers were
collected at genetic counseling and from medical records. Loss of
heterozygosity (LOH) at BRCA1 locus in tumor DNA was
performed as previously described [16].
Results
Geographical distribution and frequency of the BRCA1
c.190T.C families
The birth places of the probands of the 43 BRCA1 c.190T.C
positive families are shown in Figure 1. The majority were from
the city of Bergamo and its province (n = 23) or from neighboring
provinces of the Lombardy region (n = 16). The frequencies of
c.190T.C positive families on the total number of families tested
for BRCA1 and BRCA2 mutations and on the total number of
BRCA-positive families were 8.7% and 30.2%, respectively, in
cases recruited in Bergamo and 0.8% and 3.2%, respectively, in
cases recruited in Milan (Table 1).
Haplotype analysis
Fragment analysis of 6 microsatellite marker loci intragenic and
flanking BRCA1 identified a shared haplotype extending over 3
marker loci (0.4 cM) in carriers of the BRCA1 c.190T.C from 20
families for which DNA of more than one member was available
(Figure 2). In one additional mutated family with only one
individual available for the analysis, the observed genotypes were
compatible with the shared haplotype.
Age estimate of the BRCA1 c.190T.C mutation
The DMLE+2.2 program was used to estimate the age of the
BRCA1 c.190T.C mutation based on haplotype data from
mutation carriers and non carriers.
Three separate analyses were performed, using a population
growth rate per generation of 0.052 and different estimates of the
proportion of sampled mutation-carrying chromosomes (0.015,
0.01 and 0.005). The resulting age estimates were 124 generations
(95% credible set: 79–170), 130 generations (95% credible set: 91–
170) and 134 generations (95% credible set: 97–171), respectively
(data not shown). Assuming an interval of 25 years per generation,
this corresponds to the mutation being 3,100, 3,250 and 3,350
years old, respectively. Thus, age estimates were only slightly
affected by the actual proportion of sampled mutation-carrying
chromosomes.
Evaluation of the effect of the BRCA1 c.190T.C variant
on mRNA transcripts
The BRCA1 c.190T.C variant is mapped to an alternatively
used donor splice site. The usage of this site leads to the synthesis
of a naturally occurring isoform missing 22 bp at the 39-end of
exon 5 (Dexon5q) [17,18]. To evaluate the putative effect of the
mutation on Dexon5q and full-length transcription levels, the
cDNA region encompassing the mutation site was amplified and
analyzed by capillary electrophoresis. The ratio between the peak
areas of the Dexon5q and the full-length isoforms in LCLs carrying
the c.190T.C, cultured in the presence and in the absence of
Figure 1. Geographical distribution of BRCA1 c.190T.C (p.Cys64Arg) mutation carriers. Symbol (‘‘N’’) indicates the birth places of index
case from families segregating the mutation.
doi:10.1371/journal.pone.0086924.g001
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cycloheximide, was calculated and compared with those of wild-
type LCLs (Figure 3). The LCL carrying the BRCA1 c.212G.A
mutation previously reported to up-regulate the Dexon5q isoform
[14] was used as internal control. A significant decrease in the ratio
of the Dexon5q vs. full length expression levels was observed in the
c.190T.C LCLs compared to normal controls (0,45, 95%
CI = 0.44–0.46 and 0.52, 95%, CI = 0.50–0.54, for the CHX-
untreated and treated samples, respectively). Sequence analyses
detected the presence of the mutation in the full length cDNA
(data not shown). These results indicate that the c.190T.C
mutation does not impair the synthesis of full-length mRNA and
are consistent with a sustained expression of the mutated protein.
Evaluation of the effect of the c.190T.C mutation on the
interaction of BRCA1 with BARD1
The BRCA1 protein displays an E3 ubiquitin ligase activity
mediated by the interaction with BARD1 through its N-terminal
RING-finger domain [19,20], where the c.190T.C (p.Cys64Arg)
is located.
To assess whether the mutation affects the BRCA1/BARD1
complex formation, we carried out a GFP-fragment reassembly
screening, a Bimolecular Fluorescence Complementation-based
assay (BiFC) [21]. In this assay, the GFP is dissected into two
fragments (NfrGFP and CfrGFP) that, when expressed together in
E. coli cells, do not spontaneously reassemble into a fluorescence
Table 1. Number and frequencies of BRCA1 c.190T.C positive families among those recruited at three Italian institutions and
tested for BRCA mutations.
Institution No. identified % on total tested families* % on BRCA1/2 families
INT 22 1,03 (22/2140) 3,98 (22/553)
IEO 4 0,39 (4/1013) 1,54 (4/260)
INT+IEO 26 0,82 (26/3153) 3,20 (26/813)
AO-BG 16 8,74 (16/183) 30,19 (16/53)
*Intake criteria for BRCA testing are described in Manoukian et al [38].
doi:10.1371/journal.pone.0086924.t001
Figure 2. Haplotype branching trees in families segregating the BRCA1 c.190T.C (p.Cys64Arg). The six short tandem repeat markers
analyzed are shown together with their position in the Marshfield genetic map. Family haplotypes are indicated with the corresponding family ID
codes. The most common haplotype is indicated in bold numbers.
doi:10.1371/journal.pone.0086924.g002
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protein. However, if the two fragments of GFP are each
individually fused to two interacting proteins, this interaction
can mediate reassembly of the GFP in co-transformed bacteria
with consequent cellular fluorescence [22].
Under inducing conditions (0.2% L-arabinose and 20 mM
IPTG; Fig. 4A, left column), bright fluorescence was observed in
bacterial cells co-expressing BARD1-NfrGFP together with
BRCA1-wild type/CfrGFP or BRCA1-D67Y/CfrGFP carrying
the variant p.Asp67Tyr, previously classified as clinically neutral
[3] and the strong interacting anti-parallel Z-NfrGFP/Z-CfrGFP
fusion peptides. No fluorescence was observed in bacteria co-
expressing the following fusion peptides: non cognate BARD1
NfrGFP/CfrGFP-Z, BARD1-NfrGFP/BRCA1-C61G-CfrGFP
carrying the p.Cys61Gly disease-causing mutation [23], and
BARD1-NfrGFP/BRCA1-C64R-CfrGFP carrying the p.Cy-
s64Arg mutation. In addition, IMAC purified reassembled
Figure 3. Semi-quantitative fragment analysis of the Dexon5q isoform. The upper panel shows the capillary electrophoresis patterns of the
cDNA fragments spanning BRCA1 exons 5 and 6 observed in LCLs from a BRCA1 wild type individual, and from carriers of the c.190T.C and
c.212G.A, which causes the up-regulation of the Dexon5q transcript, mutations. The Dexon5q and full-length (FL) isoforms are indicated. The lower
panel shows the ratio between the peak areas of the Dexon5q and full-length isoforms. The LCLs were cultured in the presence (dark grey bars) and
in the absence (light grey bar) of cycloheximide. Control bars represent the average value observed in six wild-type LCLs. c.190T.C bars represent
the average value observed in four mutant LCLs. The error bars represent standard deviation.
doi:10.1371/journal.pone.0086924.g003
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complexes from the soluble fraction of co-transformed cells E. coli
BL21-(DE3) were analyzed by Western blotting (Figure 4B). Using
a polyclonal anti-GFP antibody, two strong bands corresponding
to the components of the GFP reassembled complexes were
detected in lysates of bacterial cells co-expressing Z-NfrGFP/
CfrGFP-Z and BARD1-NfrGFP together with BRCA1-wild type/
CfrGFP or BRCA1-Asp67Tyr. Much more reduced bands were
observed in cell lysates co-expressing BARD1-NfrGFP and
BRCA1-Cys61Gly/CfrGFP or BRCA1-Cys64Arg/CfrGFP. Since
unassembled GFP fusion fragments are unfolded and less soluble
[24], these results indicate GFP reassembly and, therefore,
BRCA1/BARD1 binding for the BRCA1-wt and BRCA1-
Asp67Tyr constructs, but not for the BRCA1-Cys61Gly and
BRCA1-Cys64Arg constructs. These observations are consistent
with those obtained by fluorescence complementation assay.
Unpurified cell lysates from co-transformed E. coli BL21-(DE3)
bacteria, were visualized by Western blotting with a polyclonal
anti-GFP antibody, revealing that all the fusion peptides were
expressed to a similar extent (Figure 4C). This demonstrates that
the lack of co-purification of CfrGFP-BRCA1-HA fragments for
the Cys61Gly and Cys64Arg constructs is attributable to the lack
of binding to BARD1 and not to poor expression of the BRCA1
mutants.
Clinical and pathological features of BRCA1 c.190T.C
carriers
Overall, a total of 86 ascertained mutation carriers and of 7
obligate carriers were identified in the families recruited in the
study, including 83 females and 10 males. Among female carriers,
55 (66%) reported a diagnosis of breast carcinoma (n = 38),
ovarian carcinoma (n = 12) or both breast and ovarian carcinomas
(n = 5).
Available clinical and pathological features of the affected
female carriers are reported in Table 2 and 3. The median ages of
breast cancer and ovarian cancer diagnosis were 39.6 and 48.2
years, respectively. The large majority of breast cancers were of
high grade (23/28 = 82.1%). The prevalent histological type was
ductal (32/38 = 84.2%), being the remaining cases mostly of the
medullary type (4/38 = 10.5%). The frequencies of cancers
positive for estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor 2 (HER2/Neu) were
4/31 (12.9%), 6/31 (19.4%) and 3/22 (13.6%), respectively. The
information for all the above tumor markers was available in 23
Figure 4. Detection of BRCA1/BARD1 interaction by GFP-fragment reassembly screening. (a) Fluorescence was observed after 24 h of
growth at 30uC followed by 2 days of incubation at RT. No fluorescence is observed under non-inducing condition (right column). [L-ara, L-arabinose;
IPTG, Isopropyl b-D-1-tiogalattopiranoside, IPTG]. (b) SDS-PAGE of purified, reassembled complexes by IMAC methods. The expected molecular
masses are indicated on the left. [*Non-specific band. BN, H6-NfrGFPBARD1; Z
N, H6-ZNfrGFP; Z
C, ZCfrGFP-HA]. (c) Expression of NfrGFP-BARD1 and
CfrGFP-BRCA1 wild-type and mutant forms.
doi:10.1371/journal.pone.0086924.g004
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cases, and the majority (15 = 65.2%) displayed a triple-negative
(TN) phenotype (lack of the expression of ER, PR and HER2/
Neu). The frequencies of contralateral breast cancer were 8/18
(44.4%) and 12/15 (80%) 5 and 10 years after the first diagnosis of
breast cancer, respectively. Three patients were diagnosed with
additional cancers, including one malignant mixed mullerian
tumor (MMMT) of the endometrium, one endometrial carcinoma,
and one basal cell carcinoma. As for ovarian cancers, the large
majority were of high grade (10/11 = 90.9%) and of the serous
type (9/11 = 81.8%). Of the remaining female carriers, one
reported a pheochromocytoma at 27 years, and 27 were cancer-
free at the time of last contact (mean age = 41 years).
Three cancer diagnoses were reported in male carriers, one
prostate carcinoma, one tumor of the central nervous system and
one leukemia.
LOH at BRCA1 locus was investigated in two tumors, one breast
carcinoma and the MMMT. In both cases, the loss of the
constitutional wild-type allele was observed (data not shown).
Discussion
The BRCA1 c.190T.C mutation was firstly described in a large
Polish cancer family [25]. Subsequently, it was reported in an
Italian family characterized by high prevalence of ovarian and
breast cancer cases by Willems and co-authors [26]. These authors
showed by molecular modeling that the mutation may induce
profound modifications in the structure of the BRCA1 RING
finger motif, without affecting the normal splicing pattern of the
transcripts.
A total of 43 apparently unrelated Italian families carrying the
same mutations were referred by four different Italian clinical and
university centers. The observation that a large part (23/
43 = 53%) were from the same geographic area, the province of
Bergamo in Northern Italy, strongly suggested an origin of the
mutation from a common ancestor. Consistently, the frequencies
of c.190T.C families on the total number of those that underwent
BRCA gene testing and of those carrying pathogenic BRCA1 and
BRCA2 mutations were approximately 10-fold higher in cases
recruited in Bergamo, around 85% of whom referred to be born in
the local area, compared to those observed in families recruited in
two large cancer centers in Milan, which attract patients from all
over Italy. The analysis of microsatellite marker loci revealed a
shared haplotype in 21 typed families, confirming the founder
effect hypothesis. In addition, we estimated the origin of this
mutation within a time interval ranging from 3100 to 3350 years
ago.
Interestingly, the c.190T.C affects the same nucleotide of
another mutation (c.190T.G) that strengthen an alternatively
used donor splice site in exon 5 and also disrupts a putative exonic
splicing enhancer motif. This leads the loss of the natural donor
splice site, resulting in the lack of full length expression and the up-
regulation of the naturally occurring Dexon5q isoform, predicted
to lead to the synthesis of a truncated protein [17,18]. In
agreement with previous observations [26], no such effect was
observed for the c.190T.C. Conversely, in the LCL carrying this
mutation a reduction in the relative amount of Dexon5q compared
to full length was observed. This finding and the detection of the
c.190T.C in the full-length cDNA is consistent with a stable
expression of the Cys64Arg protein in mutation carriers.
The BRCA1 p.Cys64Arg mutation is located to the gene region
coding for the RING-finger motif of the protein. The RING-finger
motif is defined by a conserved pattern of seven cysteine and one
histidine residues arranged in an interleaved fashion forming two
distinct Zn2+-binding sites termed Site I and Site II [27].
Approximately 10% of the clinically relevant mutations of BRCA1
currently reported in the Breast Cancer Information Core (BIC)
database (URL: http://research.nhgri.nih.gov/bic/) map within
the N-terminal 100 residues-RING domain, which contain the
RING motif (residues 23–76). Functional analyses have shown that
these mutations abrogate the ubiquitin-ligase activity of BRCA1
by interfering with both the heterodimerization between BRCA1
and BARD1 and the binding of E2 protein UbcH5c to the
BRCA1/BARD1 complex [28,29].
Table 2. Clinical and pathological features of BRCA1
c.190T.C related breast cancer cases.
Breast Cancers (n=43)
n %
Age at first diagnosis (years)
,36 15 34.9
36 22 51.2
.50 6 14.0
Median 39.6
Behaviour
Invasive 40 100
In situ - -
Not available 3
Histological types
Ductal 32 84.2
Lobular - -
Medullary 4 10.5
Combineda 1 2.6
Other 1 2.6
Not available 5
Histological grade
1 2 7.1
2 3 10.7
3 23 82.1
Not available 15
ER
Positive 4 12.9
Negative 27 87.1
Not available 12
PR
Positive 6 19.4
Negative 25 80.6
Not available 12
Her2/Neu
Positive 3 13.6
Negative 19 86.4
Not available 21
Triple Negative
Yes 15 65.2
Not 8 34.8
Not available 20
aDuctal and lobular type.
doi:10.1371/journal.pone.0086924.t002
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Presently, the BRCA1 p.Cys64Arg mutation is reported in the
BIC database as a variant of unknown clinical relevance. However,
in silico analysis using SIFT (URL: http://sift.jcvi.org/), Polyphen-2
(URL: http://genetics.bwh.harvard.edu/pph2/) and Align-GVGD
(URL: http://agvgd.iarc.fr/) bioinformatics tools unanimously
predicted the BRCA1 p.Cys64Arg to be deleterious. This is
consistent with the notion that Cys64Arg disrupts a critical cysteine
residue required for the ubiquitin-ligase activity of BRCA1, through
its binding to BARD1 [30]. In fact, the analysis of the three-
dimensional Nuclear Magnetic Resonance (NMR) structure of the
BRCA1/BARD1 heterodimer showed that p.Cys64Arg substitu-
tion determines a profound rearrangement of the BRCA1 39–41
amino acid residues, predicted to result into the impairment of the
BRCA1/BARD1 interaction [26].
The result of our GFP-fragment reassembly assay provided
experimental evidence that the p.Cys64Arg actually abrogates
BRCA1/BARD1 binding as the proven disease causing mutation
p.Cys61Gly [31], thus further supporting the pathogenic role of
this variant. Interestingly, another mutation affecting the same
amino acid residue (p.Cys64Gly) was previously reported to have a
similar effect [32]. In addition, our study indicates that this
functional approach might be applied to the assessment of the
clinical significance of a number of variants in cancer-predisposing
genes, implementing currently used strategies.
The median age of breast cancer diagnosis in carriers of the
c.190T.C mutation (39.7 years) was similar to that observed in
425 breast cancer patients with other pathogenic BRCA1
mutations ascertained at the institutions participating in this study
(40.1 years). Conversely, among c.190T.C carriers the median
age of ovarian cancer onset (48.2 years) was lower than that
observed in 192 BRCA1-positive ovarian cancer patients from the
same institutions (51.9 years), suggesting a possible higher risk of
ovarian cancer in carriers of the c.190T.C compared to carriers
of other BRCA1 mutations.
Breast cancers arising in BRCA1 c.190T.C mutation carriers
showed the peculiar histopathological features of the BRCA1-
related breast tumor [33,34], with a propensity to be high grade
invasive ductal or medullary carcinomas. In addition, the majority
displayed a TN phenotype. The clinical relevance of the TN
breast cancers is highlighted by the distinctive poor prognosis and
no clear options for receptor targeted treatment [35,36]. In
agreement with other reports on BRCA1 associated ovarian
carcinomas [37,38], invasive epithelial cancer of serous histology
was found to be the most common histological subtype among
BRCA1 c.190T.C mutation carriers. Although these observations
might be biased by the relative small number of ascertained
individuals and by the preferential selection of high risk subjects
referred to genetic testing, they are consistent (together with the
findings that in two examined tumors the wild type BRCA1 allele
was lost) with the c.190T.C behaving as other BRCA1 pathogenic
variants.
In conclusion, our data show that the BRCA1 c.190 T.C
missense mutation (p.Cys64Arg) is a founder mutation of clinical
relevance recurrent in high-risk families from the province of
Bergamo, accounting for a significant fraction (ca. 9%) of those
ascertained at the local city hospital. Additional studies are needed
to assess the actual proportion of carriers of this mutation in this
district and its frequency in unselected breast/ovarian cancer
patients. This will allow evaluating whether screening for the
c.190T.C mutation can be suggested as a cost-effective strategy
for the rapid identification of at-risk individuals in the Bergamo
area. In addition, they will provide a measure of associated cancer
risks, thus improving decision-making regarding clinical manage-
ment of mutation carriers.
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